|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM247725684 |
| 003 |
DE-627 |
| 005 |
20250218085003.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.03.020
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0825.xml
|
| 035 |
|
|
|a (DE-627)NLM247725684
|
| 035 |
|
|
|a (NLM)25840105
|
| 035 |
|
|
|a (PII)S1521-6616(15)00123-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Musich, Thomas
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.08.2015
|
| 500 |
|
|
|a Date Revised 08.10.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Published by Elsevier Inc.
|
| 520 |
|
|
|a Vaccine-induced mucosal antibodies are often evaluated using small volumes of secretory fluids. However, fecal matter containing mucosal IgA is abundant. We purified fecal IgA from five SIV-vaccinated and five SIV-infected rhesus macaques by sequential affinity chromatography. The purified IgA was dimeric by native PAGE, contained secretory component, and was analogous to IgA in colostrum and vaginal fluid by western blot. IgA from one infected and four vaccinated animals neutralized H9-derived SIV(mac)251 with IC(50)s as low as 1 μg/mL. Purified IgAs inhibited transcytosis and exhibited phagocytic activity, the latter significantly correlated with SIV(mac)251 Env-specific IgA in the purified samples. Among different affinity resins, peptide M was optimal compared to jacalin, anti-monkey IgA and SSL7 for IgA purification, as confirmed using tandem peptide M/anti-monkey IgA columns. Fecal IgA provided material sufficient for several assays relevant to protective efficacy, and was shown to be multifunctional. Our approach is potentially applicable to human clinical studies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, N.I.H., Intramural
|
| 650 |
|
4 |
|a Feces
|
| 650 |
|
4 |
|a Neutralization
|
| 650 |
|
4 |
|a Non-human primate mucosal IgA
|
| 650 |
|
4 |
|a Peptide M
|
| 650 |
|
4 |
|a Phagocytosis
|
| 650 |
|
4 |
|a Transcytosis inhibition
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Endotoxins
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a SAIDS Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Demberg, Thorsten
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Morgan, Ian L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Estes, Jacob D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Franchini, Genoveffa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Robert-Guroff, Marjorie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 158(2015), 2 vom: 20. Juni, Seite 127-39
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:158
|g year:2015
|g number:2
|g day:20
|g month:06
|g pages:127-39
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.03.020
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 158
|j 2015
|e 2
|b 20
|c 06
|h 127-39
|